BRPI0404050A - Use of a compound or pharmaceutically acceptable salt or ester thereof, pharmaceutical formulation, packaged formulation, compound, and method for preventing and / or treating benign prostate hyperplasia in patients in need of such prevention or treatment. - Google Patents

Use of a compound or pharmaceutically acceptable salt or ester thereof, pharmaceutical formulation, packaged formulation, compound, and method for preventing and / or treating benign prostate hyperplasia in patients in need of such prevention or treatment.

Info

Publication number
BRPI0404050A
BRPI0404050A BR0404050-3A BRPI0404050A BRPI0404050A BR PI0404050 A BRPI0404050 A BR PI0404050A BR PI0404050 A BRPI0404050 A BR PI0404050A BR PI0404050 A BRPI0404050 A BR PI0404050A
Authority
BR
Brazil
Prior art keywords
compound
prevention
pharmaceutically acceptable
ester
formulation
Prior art date
Application number
BR0404050-3A
Other languages
Portuguese (pt)
Inventor
Luciano Adorini
Enrico Colli
Original Assignee
Bioxell Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell Spa filed Critical Bioxell Spa
Publication of BRPI0404050A publication Critical patent/BRPI0404050A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"USO DE UM COMPOSTO OU DE UM SEU SAL OU éSTER FARMACEUTICAMENTE ACEITáVEL, FORMULAçãO FARMACêUTICA, FORMULAçãO ACONDICIONADA, COMPOSTO, E, MéTODO PARA PREVENIR E/OU TRATAR HIPERPLASIA BENIGNA DA PRóSTATA EM PACIENTES EM NECESSIDADE DE TAL PREVENçãO OU TRATAMENTO". O invento refere-se à utilização de 1-alfa-fluoro-25hidróxi-16,23E-dieno-26,27-bis-homo-20-epi-colecalc iferol, ou de um seu sal ou éster farmaceuticamente aceitável, para o fabrico de um medicamento para a prevenção e/ou tratamento de hiperplasia benigna da próstata (HBP) e sintomas associados."USE OF A COMPOUND OR ITS SALT OR PHARMACEUTICALLY ACCEPTABLE ESTER, PHARMACEUTICAL FORMULATION, CONDITIONED FORMULATION, AND METHOD TO PREVENT AND / OR TREAT BENEFICIAL HYPERPLASIA IN PRECENT PREVENTION OR PATIENT. The invention relates to the use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bis-homo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for the manufacture of a medicine for the prevention and / or treatment of benign prostate hyperplasia (BPH) and associated symptoms.

BR0404050-3A 2003-09-24 2004-09-22 Use of a compound or pharmaceutically acceptable salt or ester thereof, pharmaceutical formulation, packaged formulation, compound, and method for preventing and / or treating benign prostate hyperplasia in patients in need of such prevention or treatment. BRPI0404050A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (1)

Publication Number Publication Date
BRPI0404050A true BRPI0404050A (en) 2005-06-14

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0404050-3A BRPI0404050A (en) 2003-09-24 2004-09-22 Use of a compound or pharmaceutically acceptable salt or ester thereof, pharmaceutical formulation, packaged formulation, compound, and method for preventing and / or treating benign prostate hyperplasia in patients in need of such prevention or treatment.

Country Status (12)

Country Link
EP (1) EP1673096A1 (en)
JP (2) JP2007506699A (en)
CN (1) CN100488511C (en)
BE (1) BE1016292A3 (en)
BR (1) BRPI0404050A (en)
CH (1) CH698144B1 (en)
EA (1) EA010240B1 (en)
FR (1) FR2859910B1 (en)
HK (1) HK1085373A1 (en)
NL (1) NL1027109C2 (en)
NZ (1) NZ535531A (en)
WO (1) WO2005027923A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006038611A1 (en) * 2004-10-05 2008-05-15 キッセイ薬品工業株式会社 Preventive and / or therapeutic agent for urinary storage disorder associated with lower urinary tract obstruction disease
PT1806136E (en) * 2004-10-06 2012-03-08 Kissei Pharmaceutical Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906A1 (en) * 2017-03-20 2018-09-21 Pierre Fabre Medicament USE OF COPAIFERA OLEORESIN IN THE PATHOLOGIES OF THE PROSTATE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
CA2289209C (en) * 1997-05-16 2006-07-25 Women & Infants Hospital Cyclic ether vitamin d3 compounds, 1.alpha. (oh) 3-epi-vitamin d3 compounds and uses thereof
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
US20030191093A1 (en) * 2001-12-03 2003-10-09 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds

Also Published As

Publication number Publication date
HK1085373A1 (en) 2006-08-25
JP2007506699A (en) 2007-03-22
WO2005027923A1 (en) 2005-03-31
CH698144B1 (en) 2009-05-29
CN100488511C (en) 2009-05-20
NL1027109A1 (en) 2005-03-29
BE1016292A3 (en) 2006-07-04
NL1027109C2 (en) 2005-05-03
NZ535531A (en) 2006-03-31
FR2859910B1 (en) 2006-04-28
EP1673096A1 (en) 2006-06-28
FR2859910A1 (en) 2005-03-25
EA010240B1 (en) 2008-06-30
CN1615891A (en) 2005-05-18
EA200401100A1 (en) 2005-04-28
JP2009035559A (en) 2009-02-19

Similar Documents

Publication Publication Date Title
BRPI0406667A (en) Method for treating cancer, and therapeutically acceptable formulation of 2-dg
ATE307608T1 (en) COMBINATION OF DOCTAXEL AND RHUMAB HER2 FOR CANCER TREATMENT
BR0209365A (en) Pharmaceutical uses of bisphosphonates
BR0115109A (en) Therapeutic agents and methods of their use for angiogenesis modulation
BRPI0415007A (en) method for treating, preventing, modifying or administering pain and pharmaceutical composition
ATE309798T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABIDIOL DERIVATIVES
MXPA03010085A (en) Composition and methods for treatment of hyperplasia.
DE60026538D1 (en) PHARMACEUTICAL PREPARATIONS THE CLAVULANIC ACID OR DERIVATIVES CONTAIN FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
BRPI0406796A (en) Methods for treating benign prostatic hypertrophy, reducing a symptom associated with it, reducing prostate size in a human subject, and for bhp prophylaxis, oral unit dose pharmaceutical composition, and use of lonidamine or a lonidamine analogue
HK1068606A1 (en) Novel aminobenzoephenones
BR0315593A (en) Method of treating, preventing, modifying or controlling pain and pharmaceutical composition
BRPI0404050A (en) Use of a compound or pharmaceutically acceptable salt or ester thereof, pharmaceutical formulation, packaged formulation, compound, and method for preventing and / or treating benign prostate hyperplasia in patients in need of such prevention or treatment.
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
BR0315609A (en) Method of treating, preventing, modifying or controlling pain and pharmaceutical composition
TR200103418T2 (en) Therapeutic use of melatonin.
BR0211855A (en) Drug and method for treating and improving restorative sleep quality
BRPI0515668A (en) androgen deprivation-induced osteoporosis treatment
D'Andrea et al. Surgical treatment of ulcers caused by extravasation of cytotoxic drugs
Mohammad et al. Sublingual piroxicam in the management of postoperative pain after surgical removal of impacted mandibular third molar
BRPI0416266A (en) method for treating, preventing and / or controlling an asbestos-related disease or disorder in a patient

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.